Prostate News Archive
06-Jul-2007
Genaera Discontinues LOMUCIN(TM) in Cystic Fibrosis and Squalamine in Prostate Cancer Studies (PR Newswire via Yahoo! Finance)
Genaera Corporation today announced that, in conjunction with Cystic Fibrosis Foundation Therapeutics, Inc. , both parties have agreed for reasons of futility to discontinue the Phase 2 study of LOMUCIN for the treatment of cystic fibrosis . Retreat focuses on black men's health (The State Journal-Register)
There's nothing "special" about black men that causes them to be more susceptible to heart disease, prostate cancer or HIV/AIDS, according to Terry Mason, commissioner of the Chicago Department of Public Health. Genaera halts 2 studies (The Scranton Times-Tribune)
Drug developer Genaera Corp. said Thursday that it has halted studies of a cystic fibrosis treatment and a prostate cancer drug. WP: Cancer therapy delay attacked (MSNBC)
Two doctors are at the center of an unusually bitter debate over an experimental therapy for prostate cancer, ever since they helped persuade the Food and Drug Administration to delay approving it, enraging both patients and investors.
Back to Prostate News Archive
